ottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Apr. 26
MT
Top Midday Gainers
Apr. 26
MT
Sector Update: Health Care Stocks Higher in Afternoon Trading
Apr. 26
MT
In-Line Inflation Data, Tech Earnings Lift US Equity Indexes
Apr. 26
MT
Sector Update: Health Care
Apr. 26
MT
KeyBanc Adjusts Price Target on ResMed to $238 From $227
Apr. 26
MT
ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr. 26
MT
Jefferies Adjusts Price Target on ResMed to $180 From $164
Apr. 26
MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating
Apr. 26
MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198
Apr. 26
MT
Mizuho Adjusts Price Target on ResMed to $220 From $215
Apr. 26
MT
Needham Adjusts Price Target on ResMed to $236 From $224
Apr. 26
MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207
Apr. 26
MT
RBC Adjusts Price Target on ResMed to $200 From $187
Apr. 26
MT
ResMed Declares Quarterly Dividend as Fiscal Q3 Profit Jumps 29%; Shares Up 7%
Apr. 25
MT
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
Apr. 25
RE
ResMed Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Rise After Hours
Apr. 25
MT
Transcript : ResMed Inc., Q3 2024 Earnings Call, Apr 25, 2024
Apr. 25
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.
Apr. 25
CI
ResMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Apr. 25
CI
ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024
Apr. 25
CI
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap
Apr. 17
RE
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating
Apr. 01
MT
ResMed Inc. Announces the U.S. Launch of the AirFit F40
Mar. 06
CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight
Mar. 05
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
More about the company
Average target price
215.1
USD
Spread / Average Target
+0.02%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1